(19)
(11) EP 4 823 576 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 24828283.2

(22) Date of filing: 09.12.2024
(51) International Patent Classification (IPC): 
A61K 31/4725(2006.01)
A61P 29/00(2006.01)
A61P 1/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/4725; A61P 29/00; A61P 1/00
(86) International application number:
PCT/US2024/059225
(87) International publication number:
WO 2025/128492 (19.06.2025 Gazette 2025/25)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 11.12.2023 US 202363608750 P

(71) Applicant: Gilead Sciences Inc.
Foster City, California 94404 (US)

(72) Inventors:
  • WEBER, Elijah J.
    San Francisco, California 94117 (US)
  • OTHMAN, Ahmed A.
    Dublin, California 94568 (US)
  • CHANG, Ingrid J.
    Denver, Colorado 80210 (US)
  • MCKEVITT, Matthew T.
    Seattle, Washington 98144 (US)

(74) Representative: Müller, Christian Stefan Gerd 
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)

   


(54) USE OF TPL2 INHIBITORS, SUCH AS A PRODRUG OF TILPISERTIB, TO TREAT INFLAMMATORY BOWEL DISEASE OR ULCERATIVE COLITIS